DDrare: Database of Drug Development for Rare Diseases

172. 低ホスファターゼ症
［臨床試験数：32，薬物数：18（DrugBank：4），標的遺伝子数：3，標的パスウェイ数：6］

Searched query = "Hypophosphatasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ASFOTASE ALFA; Alkaline Phosphatase; Asfotas Alfa; Asfotase Alfa; Asfotase Alfa (ALXN1215); Asfotase alfa; BPS804; Biochemical analysis of different bone markers.; Cyclophosphamide; ENB-0040; Fully human IgG2 lambda monoclonal antibody; Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein; Human recombinant tissue non-specific alkaline phosphatase fusion protein; Methotrexate; Other: High resolution peripheral quantitative computed tomography (HRpQCT); Other: Microindentation; Retrospective Case Only; Strensiq

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000014816	2014/08/11	11/08/2014	A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in patients with hypophosphatasia (HPP)		hypophosphatasia	Drug: Asfotase Alfa (ALXN1215) Dose: 6mg/kg/week (divided 3 times a week)	HPP study group	Translational Research Informatics Center	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	20	Not selected	Japan
2	NCT02456038 (ClinicalTrials.gov)	August 2014	26/3/2015	Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)	A Multicenter Study of the Safety and Efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Patients With Hypophosphatasia (HPP)	Hypophosphatasia	Drug: Asfotase Alfa (ALXN1215)	Translational Research Informatics Center, Kobe, Hyogo, Japan	Osaka University Graduate School of Medicine	Completed	N/A	N/A	Both	13	Phase 2	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000014816

2014/08/11

11/08/2014

A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in patients with hypophosphatasia (HPP)

hypophosphatasia

Drug: Asfotase Alfa (ALXN1215)
Dose: 6mg/kg/week (divided 3 times a week)

HPP study group

Translational Research Informatics Center

Complete: follow-up complete

Not applicable

Male and Female

Not selected

Japan

NCT02456038
(ClinicalTrials.gov)

August 2014

26/3/2015

Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)

A Multicenter Study of the Safety and Efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Patients With Hypophosphatasia (HPP)

Hypophosphatasia

Drug: Asfotase Alfa (ALXN1215)

Translational Research Informatics Center, Kobe, Hyogo, Japan

Osaka University Graduate School of Medicine

Completed

N/A

Both

Phase 2

Japan